15.71

7.48% -1.27

After Hours: 15.72 0.010 +0.06%

Mediwound Ltd (MDWD)

Overview News Price History Option Chain Discussions Forecast Stock Split

Mediwound Ltd stock is traded at $15.71, with a volume of 223.35K. It is down -7.48% in the last 24 hours and down -10.33% over the past month. MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Previous Close:

$16.98

Open:

$16.84

24h Volume:

223.35K

Relative Volume:

2.31

Market Cap:

$201.81M

Revenue:

$16.96M

Net Income/Loss:

$-23.88M

P/E Ratio:

-7.4917

EPS:

-2.097

Net Cash Flow:

$-20.66M

1W Performance:

-7.42%

1M Performance:

-10.33%

6M Performance:

-12.19%

1Y Performance:

-4.96%

1-Day Range:

$15.70

$16.89

1-Week Range:

$15.70

$17.37

52-Week Range:

$14.14

$22.50

Mediwound Ltd Stock (MDWD) Company Profile

Name

Mediwound Ltd

Sector

Healthcare (1113)

Industry

Biotechnology (623)

Phone

Address

Employee

121

Twitter

Next Earnings Date

2025-03-19

Latest SEC Filings

MDWD's Discussions on Twitter

Compare MDWD vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MDWD Mediwound Ltd	15.71	218.12M	16.96M	-23.88M	-20.66M	-2.097
VRTX Vertex Pharmaceuticals Inc	453.74	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	756.73	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.16	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	692.83	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	147.60	31.97B	606.42M	-1.28B	-997.58M	-6.403

Mediwound Ltd Stock (MDWD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-02-25	Resumed	Oppenheimer	Outperform
May-02-25	Initiated	Alliance Global Partners	Buy
Feb-28-25	Initiated	Craig Hallum	Buy
Jul-16-24	Reiterated	Maxim Group	Buy
Dec-22-22	Initiated	Maxim Group	Buy
Jul-18-22	Resumed	Oppenheimer	Outperform
Sep-23-20	Initiated	BTIG Research	Buy
Nov-28-16	Initiated	Aegis Capital	Buy
Aug-17-16	Initiated	Wells Fargo	Outperform
Apr-16-14	Initiated	Oppenheimer	Outperform

View All

Mediwound Ltd Stock (MDWD) Latest News

Mar 25, 2026

MediWound (MDWD) director details options, RSU and share holdings - Stock Titan

Mar 25, 2026

Mar 24, 2026

MediWound Ltd. (NASDAQ:MDWD) Q4 2025 earnings call transcript - MSN

Mar 24, 2026

Mar 22, 2026

Gap Down: Can MediWound Ltd keep up with sector leaders2026 Sector Review & Smart Swing Trading Alerts - baoquankhu1.vn

Mar 22, 2026

Pullback Watch: Does MediWound Ltd meet Warren Buffetts criteriaEarnings Overview Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn

Mar 22, 2026

Mar 21, 2026

MediWound (NASDAQ:MDWD) Stock Passes Below 200-Day Moving AverageTime to Sell? - MarketBeat

Mar 21, 2026

Mar 20, 2026

Discipline and Rules-Based Execution in MDWD Response - Stock Traders Daily

Mar 20, 2026

Mar 19, 2026

Aug Drivers: Will MediWound Ltd outperform the market in YEARGap Down & Verified Short-Term Plans - baoquankhu1.vn

Mar 19, 2026

Mar 18, 2026

MediWound (MDWD) director Rubinstein reports options and share holdings - Stock Titan

Mar 18, 2026

[Form 3] MediWound Ltd. Initial Stateme... - Stock Titan

Mar 18, 2026

MediWound (MDWD) CMO details options and RSU awards in Form 3 filing - Stock Titan

Mar 18, 2026